Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: [68Ga]-LNTH-2401; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Advanced Solid Tumors
Interventions: ASP1951, pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more

Conditions: Prostate Cancer Metastatic to Bone
Interventions: Radium Ra 223 Dichloride, Radiation; Drug · Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 867 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostatic Neoplasms
Interventions: Novel hormonal therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older · Male only
Enrollment: 3,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Incontinence, Stress
Interventions: The AMS Male Transobturator Sling System, AdVance Male Sling; Device
Lead sponsor: American Medical Systems; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Ann Arbor, Michigan + 7 more

Conditions: Head and Neck Cancer, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions: Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography; Radiation · Other · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 1,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Solid Tumor
Interventions: DB-1310, Trastuzumab, Osimertinib, capecitabine; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more

Conditions: Prostatic Neoplasms
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Flutamide (Eulexin) and Lupron or Zoladex, External Beam Radiotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 41 Years and older · Male only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castrate Sensitive Prostate Cancer, Metastatic Prostate Cancer
Interventions: Home-Based Exercise Intervention - Walking, Home-Based Exercise Intervention - HIIT Cycling; Behavioral
Lead sponsor: Paul Viscuse; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Prostate Cancer
Interventions: mutation analysis; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Male only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 49
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more

Conditions: Urologic Cancer, Urologic Neoplasms, Bladder Cancer, Prostate Cancer, Testicular Cancer, Kidney Cancer, Urethral Cancer, Penile Cancer
Interventions: Electromagnetic Guided Laparoscopy, Ultrasound; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer, Prostate
Interventions: Mitoxantrone, Siltuximab, Prednisone; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Norwalk, Connecticut • Port Saint Lucie, Florida • Atlanta, Georgia + 8 more

Conditions: Prostate Cancer
Interventions: Dehydrated alcohol, Lidocaine IV; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenocarcinoma of the Prostate
Interventions: Cyclophosphamide, DRibble Vaccine, HPV Vaccinations, Imiquimod; Drug · Biological
Lead sponsor: UbiVac; Industry
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: MBM-02 (Tempol); Drug
Lead sponsor: Matrix Biomed, Inc.; Industry
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: Marina del Rey, California

Conditions: Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
Interventions: Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Elevated PSA, Prostate Cancer
Interventions: Targeted biopsy; Device
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: docetaxel, mitoxantrone hydrochloride, conventional surgery; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry; Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 40 Years to 120 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Cancer
Interventions: Cross-linked hyaluronan gel; Device
Lead sponsor: Cancer Center of Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Irvine, California

Conditions: Cancer, Fatigue, Prostate Cancer, Breast Cancer, Cancer Survivor
Interventions: Not listed
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Microarray Analysis of Gene Expression in Prostate Tissues

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence

Measuring the Effect of Radiation Therapy on Patient Activity Levels

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Magnetic Resonance Imaging to Evaluate Prostate Cancer

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Long Acting Neuraxial Peri-prostatic Block in Cancer

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer

Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer

Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers

Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer

Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors